行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

2.240
-0.020
-0.89%
盘后: 2.250 +0.01 +0.45% 19:26 01/15 EST
开盘
2.150
昨收
2.260
最高
2.280
最低
2.150
成交量
21.75万
成交额
--
52周最高
5.36
52周最低
0.6300
市值
5,977.93万
市盈率(TTM)
-4.3319
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 2020/11/13 12:40
Navidea Biopharmaceutical Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $268.00K Beat $150.00K Estimate
Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 23.53 percent increase over losses of $(0.17) per
Benzinga · 2020/11/12 21:03
Navidea Biopharma Reports Results From Added Patients For Ongoing Phase 2b Study In Rheumatoid Arthritis: 'Data Support Hypothesis that Tc99m Tilmanocept Imaging Can Provide Early Indicator of Treatment Response'
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce
Benzinga · 2020/11/12 21:03
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 2020/11/12 12:44
Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable
finviz · 2020/10/22 11:30
Navidea Biopharma Reports Abstract Accepted For Presentation At American College Of Rheumatology Meeting Nov. 9 Between 9-11 a.m. EDT
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that
Benzinga · 2020/10/09 11:33
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting
finviz · 2020/10/09 11:30
Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange
finviz · 2020/09/28 11:30
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解NAVB最新的财务预测,通过NAVB每股收益,每股净资产,每股现金流等数据分析Navidea生物制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NAVB价格均价为7.50,最高价位8.00,最低价为7.00。
EPS
机构持股
总机构数: 32
机构持股: 74.28万
持股比例: 2.78%
总股本: 2,668.72万
类型机构数股数
增持
7
15.81万
建仓
5
3.67万
减持
8
2.59万
平仓
24
8.40万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/Independent Director
Michael Rice
Chairman/Independent Director
Y. Michael Rice
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
Malcolm Witter
Independent Director
Claudine Bruck
Independent Director
Kathy Rouan
Independent Director
Adam Cutler
Independent Director
S. Kathryn Rouan
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
NAVB 简况
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.
展开
热门股票
代码
价格
涨跌幅

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NAVB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NAVB股票基本功能。